Relmada Therapeutics, Inc.

NASDAQ:RLMD

Biotechnology

Healthcare
$3.11 -0.97%

-$0.06 today

Market cap
$331.82M
Beta
0.39
P/E (TTM)
-9.6
EPS (TTM)
-$0.68
52W Low $0.52High $8.00

Volume 1.71M

Average 1.24M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$45.79M

FY 2025 · Annual

Investing Cash Flow

-$48.14M

FY 2025 · Annual

Financing Cash Flow

$93.56M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(125.75M)(157.04M)(98.79M)(79.98M)(57.39M)
Depreciation & Amortization1.26K0000
Deferred Income Tax00000
Stock-Based Compensation40.49M44.19M43.81M30.19M14.96M
Change in Working Capital(7.86M)10.59M3.08M(1.58M)(3.95M)
Accounts Receivables79.46K(426.06K)512.43K00
Inventory00000
Accounts Payables2.85M421.04K(1.76M)624.55K(2.56M)
Other Working Capital(10.79M)10.6M4.32M(2.21M)(1.39M)
Other Non-Cash Items1.25M(1.55M)241.16K(381.66K)586.18K
Operating Cash Flow(91.87M)(103.8M)(51.66M)(51.76M)(45.79M)
Capital Expenditures00(4)00
Acquisitions (Net)00000
Purchases of Investments(222.98M)(47.29M)(90.46M)(12.08M)(83.83M)
Sales of Investments168.86M67.03M140.92M63.64M35.69M
Other Investing Activities00000
Investing Cash Flow(54.12M)19.73M50.45M51.56M(48.14M)
Debt Repayment00000
Common Stock Issued185.31M42.73M0246.75K93.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.63M2.29M(98.46K)(287.09K)(73.02K)
Financing Cash Flow187.94M45.02M(98.46K)(40.34K)93.56M
Effect of Forex Changes00000
Net Change in Cash41.95M(39.05M)(1.3M)(234.54K)(360.49K)
Free Cash Flow(91.87M)(103.8M)(51.66M)(51.76M)(45.79M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$57.4M
+ D&A$0
+ Stock-Based Comp$15.0M
+ Deferred Tax$0
- Working Capital-$3.9M
+ Other Non-Cash$586.2K
= Operating Cash Flow-$45.8M
- Capex$0
= Free Cash Flow-$45.8M

Analysis

FY2025 free cash flow is -$45.8M. FCF conversion is 79.8% of net income. Operating cash flow was -$45.8M, with capex of $0. The largest bridge item is Stock-Based Comp at $15.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
4Statement of changes in beneficial ownershipSep 11, 2026
4Statement of changes in beneficial ownershipSep 11, 2026
8-KCurrent reportSep 8, 2026

Does RLMD generate free cash flow?

Relmada Therapeutics, Inc. (RLMD) generated -$45.79M of free cash flow in fiscal 2025.

How much operating cash flow does RLMD produce?

Operating cash flow was -$45.79M, before capital expenditures of $0.00.